The Sleep Apnea Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
“Sleep Apnea Pipeline Insight, 2025“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Sleep Apnea Market.
Some of the key takeaways from the Sleep Apnea Pipeline Report:
Companies across the globe are diligently working toward developing novel Sleep Apnea treatment therapies with a considerable amount of success over the years.
Sleep Apnea companies working in the treatment market are Apnimed, Eli Lilly and Company, Axsome Therapeutics/Jazz Pharmaceuticals, Bioprojet Pharma, Taisho Pharmaceutical Co., Ltd., Takeda, Bayer, Desitin Arzneimittel GmbH, and others, are developing therapies for the Sleep Apnea treatment
Emerging Sleep Apnea therapies in the different phases of clinical trials are- AD109, Tirzepatide, AD113, SUNOSI (Solriamfetol), OZAWADE (Pitolisant), TS-142, TAK-925, BAY 2586116, Sulthiame, and others are expected to have a significant impact on the Sleep Apnea market in the coming years.
In May 2025, LivaNova PLC (Nasdaq: LIVN), a leading medical technology company, today released 12-month top-line results from its OSPREY randomized controlled trial (RCT), assessing the efficacy of the aura6000™ System for treating moderate to severe obstructive sleep apnea (OSA). After 12 months of treatment, the responder rate in the therapy group was 65%, with responders defined as patients achieving at least a 50% reduction from baseline in the apnea-hypopnea index (AHI) and an AHI below 20. The study highlights a unique neurostimulation approach called proximal hypoglossal nerve stimulation (p-HGNS), which uses six electrodes placed on the proximal trunk of the hypoglossal nerve to broadly target airway muscles and allow personalized therapy adjustments.
In January 2025, Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company dedicated to developing treatments for hypertension, chronic kidney disease (CKD), and other conditions related to aldosterone imbalance, announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application. This approval allows the company to begin a Phase 2 clinical trial assessing the effects of lorundrostat in patients with moderate-to-severe obstructive sleep apnea (OSA) and hypertension. The trial is expected to commence in the first quarter of 2025.
In September 2024, Incannex Healthcare Inc. has begun dosing in the RePOSA Phase 2/3 clinical trial of IHL-42X, an oral fixed-dose combination of dronabinol and acetazolamide, for the treatment of obstructive sleep apnea (OSA). The RePOSA trial, which is randomized and double-blind, aims to evaluate the safety and efficacy of IHL-42X in OSA patients who are intolerant, non-compliant, or naïve to positive airway pressure. The Phase 2 portion is being conducted in the United States, while the expanded Phase 3 portion will include sites in the United Kingdom and European Union.
In July 2024, Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage pharmaceutical company focused on developing proprietary medicinal cannabinoid products and psychedelic-assisted psychotherapies, is excited to announce the completion of participant dosing in its IHL-42X Bioavailability/Bioequivalence (BA/BE) clinical trial.
In June 2024, Eli Lilly has disclosed the results of the SURMOUNT-OSA Phase III clinical trials, showing that tirzepatide effectively reduced the severity of moderate-to-severe OSA in obese adults, regardless of their positive airway pressure (PAP) therapy status. The multicenter, randomized, parallel, double-blind trial compared the efficacy and safety of tirzepatide against a placebo.
Sleep Apnea Overview
Sleep apnea is a common sleep disorder where breathing repeatedly stops and starts during sleep. It can cause loud snoring, gasping for air, and excessive daytime sleepiness. The two main types are obstructive sleep apnea (caused by blocked airways) and central sleep apnea (caused by brain signaling issues). If left untreated, it can lead to serious health problems like high blood pressure, heart disease, and stroke.
Get a Free Sample PDF Report to know more about Sleep Apnea Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/sleep-apnea-pipeline-insight
Emerging Sleep Apnea Drugs Under Different Phases of Clinical Development Include:
AD109: Apnimed
Tirzepatide: Eli Lilly and Company
AD113: Apnimed
SUNOSI (Solriamfetol): Axsome Therapeutics/Jazz Pharmaceuticals
OZAWADE (Pitolisant): Bioprojet Pharma
TS-142: Taisho Pharmaceutical Co., Ltd.
TAK-925: Takeda
BAY 2586116: Bayer
Sulthiame: Desitin Arzneimittel GmbH
Lemborexant: Eisai
Sleep Apnea Pipeline Therapeutics Assessment
Sleep Apnea Assessment by Product Type
Sleep Apnea By Stage and Product Type
Sleep Apnea Assessment by Route of Administration
Sleep Apnea By Stage and Route of Administration
Sleep Apnea Assessment by Molecule Type
Sleep Apnea by Stage and Molecule Type
DelveInsight’s Sleep Apnea Report covers around 14+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Sleep Apnea product details are provided in the report. Download the Sleep Apnea pipeline report to learn more about the emerging Sleep Apnea therapies
Some of the key companies in the Sleep Apnea Therapeutics Market include:
Key companies developing therapies for Sleep Apnea are – Apnimed, Eli Lilly and Company, Therapix Biosciences, Bioprojet Pharma, Axsome Therapeutics/ Jazz Pharmaceuticals and others.
Sleep Apnea Pipeline Analysis:
The Sleep Apnea pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Sleep Apnea with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Sleep Apnea Treatment.
Sleep Apnea key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Sleep Apnea Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Sleep Apnea market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Sleep Apnea drugs and therapies
Sleep Apnea Pipeline Market Drivers
Increase in prevalence of Sleep Apnea (OSA), rising awareness of the disorder are some of the important factors that are fueling the Sleep Apnea Market.
Sleep Apnea Pipeline Market Barriers
However, lack of Approved Drugs, complexity of OSA pathogenesis and other factors are creating obstacles in the Sleep Apnea Market growth.
Scope of Sleep Apnea Pipeline Drug Insight
Coverage: Global
Key Sleep Apnea Companies: Apnimed, Eli Lilly and Company, Axsome Therapeutics/Jazz Pharmaceuticals, Bioprojet Pharma, Taisho Pharmaceutical Co., Ltd., Takeda, Bayer, Desitin Arzneimittel GmbH, and others
Key Sleep Apnea Therapies: AD109, Tirzepatide, AD113, SUNOSI (Solriamfetol), OZAWADE (Pitolisant), TS-142, TAK-925, BAY 2586116, Sulthiame, and others
Sleep Apnea Therapeutic Assessment: Sleep Apnea current marketed and Sleep Apnea emerging therapies
Sleep Apnea Market Dynamics: Sleep Apnea market drivers and Sleep Apnea market barriers
Request for Sample PDF Report for Sleep Apnea Pipeline Assessment and clinical trials
Table of Contents
1. Sleep Apnea Report Introduction
2. Sleep Apnea Executive Summary
3. Sleep Apnea Overview
4. Sleep Apnea- Analytical Perspective In-depth Commercial Assessment
5. Sleep Apnea Pipeline Therapeutics
6. Sleep Apnea Late Stage Products (Phase II/III)
7. Sleep Apnea Mid Stage Products (Phase II)
8. Sleep Apnea Early Stage Products (Phase I)
9. Sleep Apnea Preclinical Stage Products
10. Sleep Apnea Therapeutics Assessment
11. Sleep Apnea Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Sleep Apnea Key Companies
14. Sleep Apnea Key Products
15. Sleep Apnea Unmet Needs
16 . Sleep Apnea Market Drivers and Barriers
17. Sleep Apnea Future Perspectives and Conclusion
18. Sleep Apnea Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsightContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
